- Home
- DQ vs VOR Comparison
DQ vs VOR Comparison
Compare DQ & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DQ | VOR |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 906.0M | 1.1B |
| IPO Year | 2010 | 2021 |
Fundamental Metrics
Financial Performance| Metric | DQ | VOR |
|---|---|---|
| Price | $14.23 | $23.54 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 10 |
| Target Price | $28.91 | ★ $45.33 |
| AVG Volume (30 Days) | 805.9K | ★ 946.2K |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $69.82 | N/A |
| Revenue Next Year | $34.34 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.38 | $1.62 |
| 52 Week High | $36.59 | $49.95 |
Technical Indicators
Market Signals| Indicator | DQ | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 57.84 | 71.43 |
| Support Level | $11.47 | $11.62 |
| Resistance Level | $17.55 | N/A |
| Average True Range (ATR) | 0.64 | 1.54 |
| MACD | 0.33 | 0.28 |
| Stochastic Oscillator | 86.11 | 98.66 |
Price Performance
Historical ComparisonAbout DQ DAQO New Energy Corp.
Daqo New Energy Corp is a polysilicon manufacturer based in China. The company manufactures and sells high-purity polysilicon to manufacturers who use it to make ingots, cells, and modules for solar power solutions. The polysilicon is packaged to meet crucible stacking, pulling, and solidification needs. All of the company's revenues come from the People's Republic of China.
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.